Atherogenic Combined Index: Validation of a Novel Predictive Lipid Biomarker for the Presence and Severity of Coronary Artery Disease

Abstract

Background/Aim. The balance between atherogenic and antiatherogenic lipid particles significantly influences coronary artery disease (CAD), as an imbalance may contribute to the development and progression of atherosclerosis, which affects the risk and severity of CAD. This study aims to introduce and validate the atherogenic combined index (ACI) as a novel lipid biomarker that, comprehensively assesses the balance between atherogenic and antiatherogenic particles in the blood to effectively reflect the cumulative atherogenic effect and its association with the presence and severity of CAD. Material and Methods. In this cross-sectional study, 1,830 patients diagnosed with CAD and a total of 650 patients without CAD were included in the study cohort for comprehensive analysis and comparison. Based on the tertiles of the SYNTAX score (SS), three subgroups of patients with CAD were identified. ACI and other atherogenic indices were compared to predict the presence and severity of CAD. Results. The levels of ACI and other non-traditional lipid markers levels were higher in the CAD group compared to the non-CAD group (p < 0.05, for all). ACI showed a good linear association with the SYNTAX score (r = 0.527; p < 0.001). The multivariate logistic regression model showed that ACI was an independent predictor of the presence (OR: 1.602, 95% CI: 1.509-1.701, p < 0.001) and severity (OR: 1.296, 95% CI: 1.243-1.351, p < 0.001) of CAD after adjustment for various confounders. Conclusion. The results suggest that ACI may serve as a promising and stronger tool for predicting the presence and severity of CAD. (c) 2024 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.